HC Wainwright Analysts Increase Earnings Estimates for MLYS

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Research analysts at HC Wainwright lifted their Q1 2025 EPS estimates for shares of Mineralys Therapeutics in a research note issued on Wednesday, April 2nd. HC Wainwright analyst M. Caufield now expects that the company will post earnings of ($0.90) per share for the quarter, up from their prior estimate of ($1.13). HC Wainwright currently has a “Buy” rating and a $42.00 price target on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Mineralys Therapeutics’ Q2 2025 earnings at ($0.88) EPS, Q3 2025 earnings at ($0.87) EPS, Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($3.50) EPS, FY2026 earnings at ($3.23) EPS, FY2027 earnings at ($3.46) EPS, FY2028 earnings at ($1.58) EPS and FY2029 earnings at $1.36 EPS.

Several other research firms have also recently issued reports on MLYS. Guggenheim reiterated a “buy” rating on shares of Mineralys Therapeutics in a research report on Monday, February 24th. The Goldman Sachs Group reduced their price target on shares of Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating on the stock in a report on Thursday, February 13th.

Mineralys Therapeutics Trading Down 2.8 %

NASDAQ MLYS opened at $12.05 on Monday. Mineralys Therapeutics has a 12 month low of $8.24 and a 12 month high of $18.38. The stock has a market cap of $756.56 million, a PE ratio of -3.31 and a beta of -0.39. The stock’s 50 day moving average is $11.94 and its 200 day moving average is $12.28.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.98) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.02.

Insiders Place Their Bets

In related news, insider David Malcom Rodman sold 55,771 shares of Mineralys Therapeutics stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $15.76, for a total value of $878,950.96. Following the completion of the transaction, the insider now owns 116,704 shares in the company, valued at approximately $1,839,255.04. This trade represents a 32.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Ra Capital Management, L.P. acquired 1,296,296 shares of Mineralys Therapeutics stock in a transaction on Thursday, March 13th. The shares were bought at an average cost of $13.50 per share, for a total transaction of $17,499,996.00. Following the completion of the purchase, the director now directly owns 4,280,051 shares of the company’s stock, valued at $57,780,688.50. The trade was a 43.45 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 84,861 shares of company stock valued at $1,142,937 in the last quarter. 33.24% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Mineralys Therapeutics

Several institutional investors have recently modified their holdings of the stock. Jennison Associates LLC raised its holdings in Mineralys Therapeutics by 55.4% during the 4th quarter. Jennison Associates LLC now owns 1,082,006 shares of the company’s stock valued at $13,319,000 after buying an additional 385,726 shares during the period. Barclays PLC increased its position in Mineralys Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 38,218 shares of the company’s stock valued at $463,000 after acquiring an additional 28,208 shares during the last quarter. Wellington Management Group LLP purchased a new stake in shares of Mineralys Therapeutics in the third quarter valued at $775,000. Proficio Capital Partners LLC bought a new stake in shares of Mineralys Therapeutics in the 4th quarter worth about $285,000. Finally, State Street Corp boosted its stake in shares of Mineralys Therapeutics by 4.0% during the 3rd quarter. State Street Corp now owns 483,766 shares of the company’s stock worth $5,858,000 after purchasing an additional 18,627 shares during the period. 84.46% of the stock is owned by institutional investors.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.